Evolus, Inc. (NASDAQ:EOLS) Shares Sold by Trexquant Investment LP

Trexquant Investment LP trimmed its position in Evolus, Inc. (NASDAQ:EOLS - Free Report) by 33.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 163,937 shares of the company's stock after selling 83,623 shares during the quarter. Trexquant Investment LP owned approximately 0.26% of Evolus worth $1,810,000 at the end of the most recent reporting period.

Several other institutional investors have also modified their holdings of the company. KBC Group NV acquired a new stake in Evolus in the fourth quarter valued at $49,000. IFP Advisors Inc increased its holdings in shares of Evolus by 17,440.7% in the 4th quarter. IFP Advisors Inc now owns 4,736 shares of the company's stock valued at $52,000 after acquiring an additional 4,709 shares during the last quarter. KLP Kapitalforvaltning AS acquired a new stake in shares of Evolus during the 4th quarter worth about $106,000. Quantbot Technologies LP purchased a new stake in Evolus during the fourth quarter worth approximately $118,000. Finally, Point72 Asset Management L.P. purchased a new stake in Evolus during the third quarter worth approximately $132,000. 90.69% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Evolus

In other news, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the stock in a transaction dated Tuesday, March 18th. The shares were sold at an average price of $13.26, for a total transaction of $60,147.36. Following the completion of the sale, the chief marketing officer now owns 95,671 shares in the company, valued at approximately $1,268,597.46. This represents a 4.53 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Moatazedi sold 6,251 shares of the firm's stock in a transaction dated Thursday, March 27th. The stock was sold at an average price of $12.40, for a total value of $77,512.40. Following the transaction, the insider now directly owns 508,619 shares in the company, valued at approximately $6,306,875.60. This represents a 1.21 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 60,575 shares of company stock worth $794,369 in the last 90 days. 6.10% of the stock is owned by insiders.

Evolus Stock Performance

NASDAQ EOLS traded up $0.26 on Monday, reaching $9.80. The stock had a trading volume of 66,818 shares, compared to its average volume of 648,300. The company has a debt-to-equity ratio of 20.58, a quick ratio of 2.23 and a current ratio of 2.47. The stock has a market cap of $623.22 million, a P/E ratio of -10.77 and a beta of 0.97. The business's 50-day moving average price is $12.91 and its 200 day moving average price is $13.31. Evolus, Inc. has a 12-month low of $8.67 and a 12-month high of $17.82.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the stock. HC Wainwright reissued a "buy" rating and set a $27.00 price objective on shares of Evolus in a report on Thursday. Barclays lifted their price target on shares of Evolus from $22.00 to $25.00 and gave the stock an "overweight" rating in a research note on Wednesday, March 5th. Finally, Needham & Company LLC restated a "buy" rating and issued a $22.00 price objective on shares of Evolus in a research note on Wednesday, April 9th.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.